Lipid metabolism-related gene ABHD5 inhibits renal cancer cell migration and invasion in vitro

Li Zeyu, Liu Hao, Huang Yuandi, Shen Kaicheng, Wang Wei, You Jinshan, Zhi Yi

PDF(4704 KB)
PDF(4704 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (06) : 701-706. DOI: 10.13406/j.cnki.cyxb.003510
Urinary system tumors

Lipid metabolism-related gene ABHD5 inhibits renal cancer cell migration and invasion in vitro

Author information +
History +

Abstract

Objective To investigated the relationship between clear cell renal cell carcinoma(ccRcc) cells and α/β-hydrolase domain-containing 5(ABHD5) during migration and invasion in vitro. Methods The TCGA database was used to analyze the expression of ABHD5 in human ccRcc tissues and normal kidney tissues. After transfection of human ccRcc cell lines 786-O and Caki-1 with ABHD5-overexpressing lentivirus, the changes in ABHD5 expression were detected using real-time PCR and Western blot. Transwell assay and scratch assay were used to examine the effects of ABHD5 on cell migration and invasion in vitro. Results TCGA database showed that the expression of ABHD5 in ccRcc tissues was significantly decreased compared with normal renal tissues(P=0.000), and the decrease was greater in recurrent metastatic tumors(P=0.007),which was significantly negatively correlated with the survival of the patients(P<0.001). Transwell assay and scratch assay showed that ABHD5 overexpression significantly inhibited the migration and invasion of ccRcc cells in vitroP<0.05). Overexpression of ABHD5 inhibited renal cancer cell migration and invasion in vitro by influencing the Sting signaling pathway. Conclusion Lipid metabolism-related gene ABHD5 inhibited the migration and invasion of ccRcc cells in vitro.

Key words

clear cell renal cell carcinoma / lipid metabolism / α/β-hydrolase domain-containing 5 / migration / invasion

Cite this article

Download Citations
Li Zeyu , Liu Hao , Huang Yuandi , et al . Lipid metabolism-related gene ABHD5 inhibits renal cancer cell migration and invasion in vitro. Journal of Chongqing Medical University. 2024, 49(06): 701-706 https://doi.org/10.13406/j.cnki.cyxb.003510

References

1
Heravi G Yazdanpanah O Podgorski I,et al. Lipid metabolism reprogramming in renal cell carcinoma[J]. Cancer Metastasis Rev202241(1):17-31.
2
Jin HR Wang J Wang ZJ,et al. Lipid metabolic reprogramming in tumor microenvironment:from mechanisms to therapeutics[J]. J Hematol Oncol202316(1):103.
3
Xia LZ Oyang L Lin JG,et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer202120(1):28.
4
Faubert B Solmonson A DeBerardinis RJ. Metabolic reprogramming and cancer progression[J]. Science2020368(6487):eaaw5473.
5
Ou JJ Miao HM Ma YY,et al. Loss of Abhd5 promotes colorectal tumor development and progression by inducing aerobic glycolysis and epithelial-mesenchymal transition[J]. Cell Rep201824(10):2795-2797.
6
Peng Y Miao HM Wu S,et al. ABHD5 interacts with BECN1 to regulate autophagy and tumorigenesis of colon cancer independent of PNPLA2[J]. Autophagy201612(11):2167-2182.
7
Gu Y Chen YR Wei L,et al. ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation[J]. Nat Commun202112(1):6711.
8
Snaebjornsson MT Janaki-Raman S Schulze A. Greasing the wheels of the cancer machine:the role of lipid metabolism in cancer[J]. Cell Metab202031(1):62-76.
9
Beloribi-Djefaflia S Vasseur S Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis20165(1):e189.
10
Reuter VE Tickoo SK. Differential diagnosis of renal tumours with clear cell histology[J]. Pathology201042(4):374-383.
11
Qi XC Li QL Che XY,et al. The uniqueness of clear cell renal cell carcinoma:summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC[J]. Front Oncol202111:727778.
12
Chen GH Zhou GL Aras S,et al. Loss of ABHD5 promotes the aggressiveness of prostate cancer cells[J]. Sci Rep20177:13021.
13
Wang X Liu MY Zhang JF,et al. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder[J]. Cell Metab202234(8):1088-1103.
14
Zhu ZC Zhou X Du HW,et al. STING suppresses mitochondrial VDAC2 to govern RCC growth independent of innate immunity[J]. Adv Sci202310(3):e2203718.
15
Hu J Sánchez-Rivera FJ Wang ZH,et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma[J]. Nature2023616(7958):806-813.

Comments

PDF(4704 KB)

Accesses

Citation

Detail

Sections
Recommended

/